Sotera Health officer sells 150,000 shares

Sotera Health Co officer Michael P. Rutz, President of Sterigenics, reported a sale of 150,000 shares of common stock on 2026-08-07 in an open-market or private transaction.

Rhea-AI Filing Summary

Sotera Health Co officer Michael P. Rutz, President of Sterigenics, reported a sale of 150,000 shares of common stock on 2026-08-07 in an open-market or private transaction. The sale was executed at a weighted-average price of $18.835 per share, with individual trades between $18.75 and $18.9050. Following this transaction, Rutz reports 334,279 shares of Sotera Health common stock held directly.

Insider Trade Summary

Net Seller: 150,000 shares

Net Sell 1 txn

Insider Rutz Michael P

Role President of Sterigenics

Sold 150,000 shs ($2.83M)

Type	Security	Shares	Price	Value
Sale	Common Stock, $0.01 par value per share F1	150,000	$18.835	$2.83M

Holdings After Transaction: Common Stock, $0.01 par value per share — 334,279 shares (Direct)

Footnotes (1)

1. F1. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $18.75 - $18.9050. The reporting person hereby undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 150,000 shares Weighted-average sale price: $18.835 per share Sale price range: $18.75 - $18.9050 per share +2 more

5 metrics

Shares sold 150,000 shares Non-derivative common stock sale on 2026-08-07

Weighted-average sale price $18.835 per share Average price across reported sale trades

Sale price range $18.75 - $18.9050 per share Range of prices for individual trades in the sale

Shares owned after transaction 334,279 shares Directly held common shares following the sale

Par value $0.01 per share Par value of Sotera Health common stock

Key Terms

weighted-average price, par value, non-derivative, open market or private transaction

4 terms

weighted-average price financial

"Price reported constitutes the average weighted price of shares sold."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

par value financial

"Common Stock, $0.01 par value per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

non-derivative financial

"transaction_type": "non-derivative""

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Sotera Health Co (SHC) report for Michael P. Rutz?

Sotera Health Co reported that Michael P. Rutz, President of Sterigenics, sold 150,000 shares of common stock on 2026-08-07. The transaction was a reported sale in an open-market or private transaction and is disclosed on a Form 4 filing.

At what price were Michael P. Rutz’s Sotera Health (SHC) shares sold?

The reported sale was at a weighted-average price of $18.835 per share, with individual trades executed between $18.75 and $18.9050. The footnote states that full price-by-price details are available upon request.

How many Sotera Health (SHC) shares does Michael P. Rutz hold after this transaction?

After the reported sale, Michael P. Rutz holds 334,279 shares of Sotera Health common stock directly. This figure represents his reported direct ownership following the 150,000-share disposition on 2026-08-07.

Was the Sotera Health (SHC) insider sale by Michael P. Rutz under a Rule 10b5-1 plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating a trading plan. Based on the filing, the sale is not identified as being made under a Rule 10b5-1 trading arrangement.

What type of security did Michael P. Rutz trade in Sotera Health (SHC)?

The transaction involved Common Stock, $0.01 par value per share of Sotera Health Co. It is reported as a non-derivative security transaction, meaning it does not involve options or other derivative instruments.

Was Michael P. Rutz’s Sotera Health (SHC) transaction direct or indirect ownership?

The Form 4 reports the ownership type as direct (code "D"). This indicates the 150,000 shares sold and the 334,279 shares remaining are held directly by Michael P. Rutz, not through a separate entity or trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/11/2026 - 04:25 PM Accepted by SEC EDGAR 08/11/2026 - 04:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rutz Michael P

(Last) (First) (Middle)

C/O SOTERA HEALTH COMPANY

9100 SOUTH HILLS BLVD, SUITE 300

(Street)

BROADVIEW HEIGHTS OHIO 44147

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sotera Health Co [ SHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President of Sterigenics

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value per share	08/07/2026		S		150,000	D	$18.835(1)	334,279	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $18.75 - $18.9050. The reporting person hereby undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Remarks:

Exhibit 24.1 - Power of Attorney

	Gregory S. Harvey, Attorney-in-Fact	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)